December5 , 2021

Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech

Related

Share

In January this 12 months, Covaxin was authorised for emergency use in India for individuals aged 18 and above

New Delhi:

Commenting on the research of the Lancet Infectious Diseases on the effectiveness of COVAXIN (BBV152) towards symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has mentioned that the outcomes evaluate nicely with 65.2 per cent efficacy towards Delta variant obtained throughout managed part 3 scientific trials of COVAXIN performed among the many normal inhabitants.

“These results compare well with the 65.2 per cent efficacy against the delta variant obtained during the controlled phase III clinical trials of COVAXIN conducted among the general population. This study also shows that COVAXIN meets the WHO efficacy criteria for COVID-19 vaccines for the dreaded Delta variant,” Bharat Biotech mentioned.

Two doses of COVID-19 vaccine Covaxin (BBV152) are 50 per cent efficient towards symptomatic COVID-19 illness, based on the primary real-world evaluation of the COVID-19 vaccine revealed within the Lancet Infectious Diseases journal.

The research assessed 2,714 hospital staff on the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15-May 15, who have been symptomatic and underwent RT-PCR take a look at for COVID-19 detection.

“2714 symptomatic tested participants remained, of whom 1,617 tested positive for SARS-CoV-2 and 1,097 tested negative,” the research mentioned.

“The unadjusted effectiveness of two doses of BBV152 against symptomatic RT-PCR-confirmed SARS-CoV-2, with an interval of at least 14 days between administration of the second dose and day of testing, was 53 per cent. After adjustment, the effectiveness was estimated to be 50 per cent. The adjusted effectiveness of two doses administered at least 28 days before testing was 46 per cent and administered at least 42 days before testing was 57 per cent,” it mentioned.

In January this 12 months, Covaxin was authorised for emergency use in India for individuals aged 18 and above. The World Health Organization (WHO) added the vaccine to its listing of authorised emergency use COVID-19 vaccines earlier this month.

(Except for the headline, this story has not been edited by NDTV workers and is revealed from a syndicated feed.)

x